S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
S&P 500   4,212.84 (+0.79%)
DOW   33,091.43 (+0.56%)
QQQ   350.00 (+0.58%)
AAPL   179.33 (+1.17%)
MSFT   329.60 (+0.37%)
META   268.76 (+1.53%)
GOOGL   122.93 (+0.05%)
AMZN   121.84 (+1.04%)
TSLA   203.70 (-0.11%)
NVDA   392.61 (+3.77%)
NIO   7.56 (+0.40%)
BABA   82.97 (+4.30%)
AMD   119.37 (+0.98%)
T   15.86 (+0.83%)
F   12.10 (+0.83%)
MU   68.95 (+1.10%)
CGC   0.85 (+2.35%)
GE   104.35 (+2.78%)
DIS   88.37 (+0.47%)
AMC   4.63 (+2.89%)
PFE   38.13 (+0.29%)
PYPL   62.91 (+1.48%)
NFLX   400.79 (+1.41%)
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

$320.26
-3.31 (-1.02%)
(As of 11:39 AM ET)
Compare
Today's Range
$320.01
$324.58
50-Day Range
$304.75
$350.40
52-Week Range
$243.17
$354.46
Volume
431,958 shs
Average Volume
1.24 million shs
Market Capitalization
$82.48 billion
P/E Ratio
25.50
Dividend Yield
N/A
Price Target
$352.59

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
9.4% Upside
$353.87 Price Target
Short Interest
Healthy
1.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.82mentions of Vertex Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$18.94 M Sold Last Quarter
Proj. Earnings Growth
7.35%
From $13.06 to $14.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

475th out of 1,006 stocks

Pharmaceutical Preparations Industry

227th out of 492 stocks


VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

MarketBeat Week in Review – 5/15 - 5/19 (VRTX)
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
2 Top Trends to Invest $5,000 in Right Now
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Vertex Pharmaceuticals Rally Likely Not Over
See More Headlines

VRTX Price History

VRTX Company Calendar

Last Earnings
5/01/2023
Today
6/01/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
4,800
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$353.87
High Stock Price Forecast
$456.00
Low Stock Price Forecast
$285.00
Forecasted Upside/Downside
+9.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
16 Analysts

Profitability

Net Income
$3.32 billion
Pretax Margin
45.28%

Debt

Sales & Book Value

Annual Sales
$9.21 billion
Cash Flow
$13.72 per share
Book Value
$56.04 per share

Miscellaneous

Free Float
256,779,000
Market Cap
$83.34 billion
Optionable
Optionable
Beta
0.49

Social Links


Key Executives

  • Reshma KewalramaniReshma Kewalramani
    President, Chief Executive Officer & Director
  • Stuart A. ArbuckleStuart A. Arbuckle
    Chief Operating Officer & Executive Vice President
  • Charles F. WagnerCharles F. Wagner
    Chief Financial Officer & Executive Vice President
  • David Matthew Altshuler
    Chief Scientific Officer & EVP-Global Research
  • Mark Bunnage
    Senior Vice President & Head-Research













VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2023?

16 analysts have issued 12 month price objectives for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $285.00 to $456.00. On average, they expect the company's share price to reach $353.87 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2023?

Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX shares have increased by 12.0% and is now trading at $323.57.
View the best growth stocks for 2023 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Monday, May, 1st. The pharmaceutical company reported $3.05 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.54. The pharmaceutical company earned $2.37 billion during the quarter, compared to analysts' expectations of $2.34 billion. Vertex Pharmaceuticals had a net margin of 35.40% and a trailing twelve-month return on equity of 25.06%. Vertex Pharmaceuticals's revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.16 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.55 billion-$9.70 billion, compared to the consensus revenue estimate of $9.71 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.28%), FMR LLC (6.32%), State Street Corp (4.74%), Wellington Management Group LLP (2.92%), Price T Rowe Associates Inc. MD (2.56%) and Geode Capital Management LLC (2.10%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $323.57.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $83.34 billion and generates $9.21 billion in revenue each year. The pharmaceutical company earns $3.32 billion in net income (profit) each year or $12.56 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 4,800 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -